European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
PubWeight™: 1.39‹?›
| Rank: Top 5%
Published in Ann Oncol on December 01, 2021
Authors
I Vergote1, A González-Martín2, I Ray-Coquard3, P Harter4, N Colombo5, P Pujol6, D Lorusso7, M R Mirza8, B Brasiuniene9, R Madry10, J D Brenton11, M G E M Ausems12, R Büttner13, D Lambrechts14, European experts’ consensus group
Author Affiliations
1: Division of Gynaecological Oncology, Department of Gynaecology and Obstetrics and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. Electronic address: ignace.vergote@uzleuven.be.
2: Clinica Universidad de Navarra, Madrid, Spain; Program for Solid Tumors at Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
3: Medical Oncology, Centre Leon Bérard and Université Claude Bernard Lyon, Lyon, France.
4: Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
5: University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy.
6: Montpellier Faculty of Medicine, University Hospital of Montpellier, Montpellier, France.
7: Department of Women and Child Science and Public Health, Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
8: Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
9: Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, Vilnius, Lithuania.
10: Oncological Gynaecology Department, Poznan University of Medical Sciences, Poznan, Poland.
11: Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
12: Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
13: Institute of Pathology, University Hospital Cologne, Cologne, Germany.
14: Department of Human Genetics, VIB and KU Leuven, Leuven, Belgium.
Articles by these authors ⇆